Andrade P, Noblesse LHM, Temel Y, Ackermans L, Lim LW, Steinbusch HWM, Visser-Vandewalle V. Neurostimulatory and ablative treatment options in major depressive disorder: a systematic review.
Acta Neurochir (Wien) 2010;
152:565-77. [PMID:
20101419 PMCID:
PMC2844529 DOI:
10.1007/s00701-009-0589-6]
[Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2009] [Accepted: 12/22/2009] [Indexed: 12/31/2022]
Abstract
INTRODUCTION
Major depressive disorder is one of the most disabling and common diagnoses amongst psychiatric disorders, with a current worldwide prevalence of 5-10% of the general population and up to 20-25% for the lifetime period.
HISTORICAL PERSPECTIVE
Nowadays, conventional treatment includes psychotherapy and pharmacotherapy; however, more than 60% of the treated patients respond unsatisfactorily, and almost one fifth becomes refractory to these therapies at long-term follow-up.
NONPHARMACOLOGICAL TECHNIQUES
Growing social incapacity and economic burdens make the medical community strive for better therapies, with fewer complications. Various nonpharmacological techniques like electroconvulsive therapy, vagus nerve stimulation, transcranial magnetic stimulation, lesion surgery, and deep brain stimulation have been developed for this purpose.
DISCUSSION
We reviewed the literature from the beginning of the twentieth century until July 2009 and described the early clinical effects and main reported complications of these methods.
Collapse